Member Info for Moorscloud

The board is being infested by parasites again! Strange! Not.

Abarren so does not deserve the attention but nicely done JHFH, very nicely done.

Wonderful for us that Abarren's miserable attempts to undermine and cause doubt merely result in Haywain giving us yet more reasons to feel secure about Hemo's science and progress. We are blessed.

It is quite interesting having unflitered Aldebarren NOT because of anything he has to say but because it is such a study of written nastiness and transparent agenda.

It's now got to the pleasing stage that I'm wanting to see the squirms in the green boxes.! Is there any way to turn them all back on or does it have to be done one by one?

"fully in line with our identity as a life-saving company." The words of a man who knows.

AI again: The market for relapsed/refractory (R/R) Acute Myeloid Leukemia (AML) treatments is a growing, significant segment of the overall AML market. While the exact size of the R/R specific market isn't provided, the total global AML treatment market was estimated at $3.47 billion in 2024 and is projected to grow to $6.29 billion by 2030

Late-breaking abstract submission dates, 15th to 29th October.

Haywain, would there be much advantage to Vlad / Hemo / shareholders to wait until phase 2/3 before making deals and in your experience do you feel anyone who wishes to deal with Hemo will want to wait that long?

To put another way, wouldn’t a deal on HGCT1 and CDX and keeping CBR be the best option for lths?

Couldn’t Hemo do deals on HGCT1 and CDX and keep full control of CBR?

What an interesting situation then! Imminent Cohort 1 news will provide proof of the safety and efficacy of HG-CT-1 and thereby give proof of concept for CDX...

Haywain - is CDX therefore complementary or competition for HG-CT-1, or neither?

Things do feel different now. Until recently it was clear to traders that they could make the sp both rise and fall and exploit the shifts. JHFH has explained very clearly and convincingly why their ability to do this is much reduced and it's clear that he and Haywain and others have done a great job too in making better investors aware of Hemo's position and potential. And it must be true that a good RNS which provides proof about the safety and efficacy of the treatment for all 3 patients in cohort 1 will raise Hemo's CAR-T desirability significantly and that there are companies out there who would love to add a potential cure for AML to their products. So it is (very) easy to feel that interest and the sp will continue to grow until and after the RNS and that the sp can double this week to £16 and fly with the RNS next Tuesday (my guess). The question - asked by Bline or Blastoid ? - is do those who wish to bring the sp down to buy in at a better price, still have the means to do so?

Can’t imagine what is must be like to have intellect and drive like that - really hope they also have the headspace to enjoy their progress and achievements. Someone once suggested Vlad should get a knighthood; supposing that’s not possible but wonder what scientific / social recognitions could happen.

Quite agree Chris0123, not acceptable, needs sorting.

Share your optimism for coming weeks: you putting in a date in AH's RNS sweepstake? :)

A pleasure to agree wholeheartedly with HT.

Thank you again Haywain and JHFH etc. Hadn't realised how appropriate the battle terminology is until now but it seems pretty clear: one the one side, people who have invested in a company whose goal is to save the lives of adults and children battling cancer; on the other, those who think and have very probably said "Calm down dear, this is only about making money". Glad to be on the side of the righteous.

"Well mr Jinx - you could be right..." Love it.

Thanks BBB11, great to hear there are investors out there who know how to fight the trader-shorter pack and are actively doing so. For those of us who know not how to fight back (and probably couldn't anyway), I suppose the best we can do to help, is hold strong and not sell.